Latest Conference Articles

AsclepiX lead candidate holds potential for wet AMD, DME, RVO (ASRS 2020)

AsclepiX lead candidate holds potential for wet AMD, DME, RVO (ASRS 2020)

July 31st 2020

ASRS

Theresa Heah, MD, provides an update on AsclepiX’s AXT107, which is derived from a cryptic peptide within collagen IV that works by activating naturally existing, homeostatic mechanisms of angiogenesis.

Assessing the angle: Getting back to basics

Assessing the angle: Getting back to basics

July 30th 2020

GLAUCOMA 360

How gonioscopy can offer ophthalmologists an option in treating patients with glaucoma

Alcon showcases latest retina innovations, data (ASRS 2020)

Alcon showcases latest retina innovations, data (ASRS 2020)

July 30th 2020

ASRS

ASRS 2020: Josh Anderson speaks on the highlights from Alcon, including new data on the performance benefits of the Hypervit dual blade 20,000 cpm probe and the launch of the NGENUITY 1.4 upgrade.

What Aviceda’s lead candidate AVD-104 may mean for dry AMD (ASRS 2020)

What Aviceda’s lead candidate AVD-104 may mean for dry AMD (ASRS 2020)

July 30th 2020

ASRS

Derek Kunimoto, MD, JD, focuses on Aviceda's technology, which will aim to target various immune system responses that contribute to pathology associated with dry AMD.

Evaluating 3-year-recurrence rate in non-infectious posterior segment veitis post-FAi

Evaluating 3-year-recurrence rate in non-infectious posterior segment veitis post-FAi

July 29th 2020

ASRS

Dilraj Grewal, MD, associate professor of ophthalmology at Duke Eye Center/ director of grading at the Duke Reading Center, speaks on his presentation "Evaluating the True 3-Year Recurrence Rate in Non-infectious Posterior Segment Uveitis Following an Injectable Fluocinolone Acetonide Insert," during the virtual 2020 ASRS meeting.

Developing a new therapy: Where do we go from here?

Developing a new therapy: Where do we go from here?

July 29th 2020

GLAUCOMA 360

Researchers must weigh emotional, financial, and reputational considerations

PDS with ranibizumab signals paradigm shift in treatment of nAMD

PDS with ranibizumab signals paradigm shift in treatment of nAMD

July 28th 2020

ASRS

ASRS 2020 coverage: Peter Campochiaro, MD, detailed findings of phase 2 of the Ladder Trial and ongoing Archway Trial during the virtual 2020 American Society of Retina Specialists (ASRS) annual meeting.

Protocol T Extension Study shows long-term visual declines in DME eyes

Protocol T Extension Study shows long-term visual declines in DME eyes

July 28th 2020

ASRS

ASRS 2020 coverage: The results of the Protocol T Extension Study underscore the need for methods to improve long-term visual gains in eyes with diabetic macular edema, according to Dante Pieramici, MD,on behalf of the DRCR Retina Network.

Traditional glaucoma surgery in the era of MIGS procedures

Traditional glaucoma surgery in the era of MIGS procedures

July 28th 2020

GLAUCOMA 360

Trabeculectomy may offer better results with more severe glaucoma

Trial shows faricimab blocks ANG-2, VEGF-A

Trial shows faricimab blocks ANG-2, VEGF-A

July 27th 2020

ASRS

ASRS 2020 coverage: Carl Danzig, MD, presented results of phase 2 Stairway Trial during the virtual 2020 American Society of Retina Specialists (ASRS) annual meeting. Faricimab is a bispecific antibody that simultaneously inhibits angiopoietin-2 and vascular endothelial growth factor A.